PMC7446504_01
Computed tomography imaging of hepatic metastasis before and after alectinib. In row 1, the circled hepatic lesion in the right lobe of the liver at baseline (A) before alectinib decreased in size (B) 2 months after alectinib. Similarly, row 2 shows a different metastatic hepatic lesion (C) before alectinib with continued response seen (D) after 2 months of alectinib. The patient experienced progression during alectinib treatment after 5 months and experienced progression during fluorouracil, folic acid, oxaliplatin, and irinotecan treatment shortly thereafter.
PO.19.00365f1.jpg
PMC7446504_01_PO.19.00365f1.jpg
fig1
The 2-month follow-up CT imaging showed continuing response (Fig 1).
(A) Chronologic timeline of events including dates of initiation of anaplastic lymphoma kinase (ALK) inhibitor and radiographic imaging. (B) Graphic description of change in tumor size over time with respect to type of therapy. #, dose number; 3w, 3-week; CT, computed tomography; FOLFIRINOX, fluorouracil, folic acid, oxaliplatin, and irinotecan; PET, positron emission tomography; R, right; US, ultrasound.
PO.19.00365f2.jpg
PMC7446504_01_PO.19.00365f2.jpg
fig2
The patient's disease has been stable on lorlatinib on 2-month follow-up imaging, and she continues to be treated with lorlatinib (Figs 2 and 3).
Computed tomography imaging of hepatic metastasis before and after lorlatinib. In row 1, the circled hepatic lesion after disease progression on fluorouracil, folic acid, oxaliplatin, and irinotecan (A) before lorlatinib was stable in size (B) 2 months after lorlatinib treatment. Similarly, row 2 shows a different metastatic hepatic lesion (C) before lorlatinib with stable disease (D) after 2 months of lorlatinib. The patient currently continues to be treated with lorlatinib.
PO.19.00365f3.jpg
PMC7446504_01_PO.19.00365f3.jpg
fig3
The patient's disease has been stable on lorlatinib on 2-month follow-up imaging, and she continues to be treated with lorlatinib (Figs 2 and 3).